Concurrent cisplatin/etoposide (PE) and twice-daily thoracic radiotherapy (BID TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited-stage small cell lung cancer - Kubota,K.; Itoh,R.; Kodama,T. (Proc ASCO, 1999)